Dr. Hamilton on the Impact of Biosimilars in Oncology

Erika P. Hamilton, MD
Published: Tuesday, Nov 12, 2019



Erika P. Hamilton, MD, director, Breast Cancer Program, Sarah Cannon Research Institute, discusses the impact of biosimilars in oncology.

Hamilton believes biosimilars are going to become increasingly used in oncology. At the moment, the presence of biosimilars is not significantly impacting the price of drugs on the market because there is not much competition; however, Hamilton believes that is going to change and eventually biosimilars will help drive down healthcare costs.

Hamilton does not personally have any concerns with using biosimilars and feels they have been proven equal to the original agents. In fact, Sarah Cannon Research Institute faculty are currently utilizing trastuzumab (Herceptin) biosimilars in the clinic now, Hamilton concludes.
SELECTED
LANGUAGE


Erika P. Hamilton, MD, director, Breast Cancer Program, Sarah Cannon Research Institute, discusses the impact of biosimilars in oncology.

Hamilton believes biosimilars are going to become increasingly used in oncology. At the moment, the presence of biosimilars is not significantly impacting the price of drugs on the market because there is not much competition; however, Hamilton believes that is going to change and eventually biosimilars will help drive down healthcare costs.

Hamilton does not personally have any concerns with using biosimilars and feels they have been proven equal to the original agents. In fact, Sarah Cannon Research Institute faculty are currently utilizing trastuzumab (Herceptin) biosimilars in the clinic now, Hamilton concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x